Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC) - Traina, T A; OʼShaughnessy, J; Nanda, R (Cancer Res, 2015)